2026/10/14 更新

写真a

シジュウボウ ナオキ
四十坊 直貴
所属
医学部 病理学講座病理学第一分野 助教
職名
助教
外部リンク

論文

  • Tumor Stroma Infiltrating T Cells Predict the Efficacy of Anti-CTLA-4 Antibody in NSCLC. 国際誌

    Hiroshi Saijo, Yoshihiko Hirohashi, Toshiyuki Sumi, Naoki Shijubo, Astushi Saito, Osamu Honjo, Toyohiro Saikai, Hirotsugu Takabatake, Akihisa Fujita, Yasuhito Honda, Hiroyuki Koba, Hirofumi Chiba, Toshihiko Torigoe

    Anticancer research   46 ( 1 )   301 - 308   2026年1月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: Although various therapeutic options are available for advanced or recurrent non-small cell lung cancer (NSCLC), the optimal criteria for selecting combination therapies involving anti-programmed death-1 (PD-1) or anti-programmed death ligand-1 (PD-L1) antibodies with anti-cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) antibodies remain unclear. Clinical trials suggest potential benefits of the treatment with anti-CTLA-4 antibodies in NSCLC with PD-L1 <1%; however, concerns persist regarding the increased risk of immune-related adverse events (irAEs). Therefore, identifying reliable biomarkers to guide the use of anti-CTLA-4 antibodies is crucial. PATIENTS AND METHODS: We performed immunohistochemical staining to assess intratumoral tumor-infiltrating lymphocytes (iTILs) and stromal tumor-infiltrating lymphocytes (sTILs) expressing CD8 or FOXP3 using surgically obtained specimens. The association between these cells and the clinical efficacy of the treatment with nivolumab plus ipilimumab was evaluated using univariate and multivariate analyses in NSCLC patients with PD-L1 <1%. Kaplan-Meier analysis was conducted to assess survival outcomes. RESULTS: Univariate analysis revealed a significant correlation between progression-free survival and sTIL infiltration, but not iTIL infiltration. Patients who responded to therapy exhibited significantly higher CD8+ and lower FOXP3+ iTIL infiltration, as reported previously. Notably, responders also demonstrated significantly higher infiltration of both CD8+ and FOXP3+ sTILs. Moreover, high stromal infiltration of CD8+ T cells was significantly associated with prolonged overall survival, while high FOXP3+ sTILs infiltration showed a trend toward improved overall survival. CONCLUSION: Despite the increased risk of irAEs, patients with high stromal infiltration of CD8+ and FOXP3+ T cells may derive meaningful clinical benefit from anti-CTLA-4 antibody therapy. Assessing these immune parameters could aid in appropriate patient selection and contribute to optimizing therapeutic outcomes.

    DOI: 10.21873/anticanres.17944

    PubMed

    researchmap

  • Automated spatial analysis reveals proximity of human leukocyte antigen class I-positive tumor cells and CD8-positive cells of the tumor microenvironment in stage I seminoma. 国際誌

    Takuto Ogasawara, Terufumi Kubo, Kenta Sasaki, Naoki Shijubou, Rena Morita, Kenji Murata, Kohei Hashimoto, Tomohide Tsukahara, Hiroko Asanuma, Toshihiko Torigoe, Reiko Watanabe, Naoya Masumori, Yoshihiko Hirohashi

    Pathology, research and practice   276   156270 - 156270   2025年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The testis is an immune-privileged organ due to its lack of functional human leukocyte antigen (HLA) class I expression. However, the expression status of HLA class I in testicular seminoma, which is characterized histologically by lymphocytic infiltration, remains unclear. MATERIALS AND METHODS: We performed immunohistochemistry to evaluate HLA class I expression and its spatial relationship with CD8-positive cells in 20 cases of stage I seminoma. Each specimen was scored manually and further analyzed using the HALO image analysis platform. RESULTS: Manual scoring and HALO analysis showed 80 % concordance. HLA class I expression was positive in 13 cases (65 %). Tumors were classified into three categories based on the expression levels. The number of infiltrating CD8-positive cells was significantly correlated with HLA class I expression. Spatial analysis revealed that tumors with higher HLA class I expression had shorter distances between HLA class I-positive tumor cells and CD8-positive cells. CONCLUSION: Seminoma cells expressing HLA class I tended to be located in close proximity to CD8-positive T cells, suggesting a spatial relationship that might influence the tumor immune microenvironment.

    DOI: 10.1016/j.prp.2025.156270

    PubMed

    researchmap

  • Characteristic TARC/CCL17 expression in the salivary gland of IgG4-related disease: potential diagnostic utility and insights into pathogenesis. 国際誌

    Nanako Kikuchi, Sae Hatanaka, Terufumi Kubo, Ryuta Kamekura, Masatoshi Kanda, Takuya Kakuki, Takashi Sasaya, Kengo Mita, Hiroki Kobayashi, Hajime Ikai, Kenta Sasaki, Naoki Shijubou, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yoshihiko Hirohashi, Tadashi Hasegawa, Akihiro Miyazaki, Hiroki Takahashi, Ken-Ichi Takano, Toshihiko Torigoe

    Immunological medicine   48 ( 3 )   226 - 232   2025年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Immunoglobulin G4-related disease (IgG4-RD) is a chronic inflammatory condition of unknown etiology characterized by lymphocytic infiltration, fibrosis, and infiltration of IgG4-positive plasma cells. It affects various organs, including the pancreas and salivary glands. Immunological abnormalities are suspected to play a role in its pathogenesis, and there is an epidemiological link to allergic conditions and type 2 inflammation. This study focused on the expression of thymus and activation-regulated chemokine (TARC)/CCL17, which is involved in the migration of T helper 2 and/or regulatory T cells, in salivary gland tissues of patients with IgG4-RD. We analyzed 60 salivary gland biopsy samples obtained from patients at Sapporo Medical University Hospital between 2015 and 2020. Immunohistochemical analysis revealed TARC/CCL17 positivity in 87.2% of histologically confirmed IgG4-RD cases and negativity in 84.6% of histologically unconfirmed but clinically suspected IgG4-RD cases. There was a significant correlation between histologically confirmed IgG4-RD and TARC/CCL17 expression, suggesting its potential diagnostic utility and possible involvement in the pathogenesis of IgG4-RD.

    DOI: 10.1080/25785826.2025.2460910

    PubMed

    researchmap

  • Early pseudo-progression of brain metastases following tarlatamab therapy in relapsed small cell lung cancer. 国際誌

    Naoki Shijubou, Toshiyuki Sumi, Taiki Ishigooka, Taeka Naraoka, Kazuya Takeda, Yuichi Yamada, Hirofumi Chiba

    Lung cancer (Amsterdam, Netherlands)   207   108730 - 108730   2025年9月

     詳細を見る

  • The size of CD8+ infiltrating T cells is a prognostic marker for esophageal squamous cell carcinoma. 国際誌

    Kengo Shigehara, Noriko Kawai, Tomohide Shirosaki, Yuma Ebihara, Aiko Murai, Akari Takaya, Serina Tokita, Kenta Sasaki, Naoki Shijubou, Terufumi Kubo, Kenji Murata, Takayuki Kanaseki, Tomohide Tsukahara, Yutaka Hatanaka, Tomoko Mitsuhashi, Toshiaki Shichinohe, Yoshihiko Hirohashi, Satoshi Hirano, Toshihiko Torigoe

    Scientific reports   15 ( 1 )   26638 - 26638   2025年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    In many malignancies, an increased number of tumor-infiltrating lymphocytes (TILs) is recognized as a favorable prognostic factor, with exceptions such as renal cell carcinoma. However, the clinical significance of TIL size remains unclear. T-cell activation by mitogens increases cell size, partly via c-myc expression, suggesting that larger T cells may be more activated. We hypothesized that TIL size might be prognostically relevant in cancer patients. Here, we examined the relationship between the size and number of tumor-infiltrating CD8 + T cells and patient prognosis in 96 cases of esophageal squamous cell carcinoma (ESCC). We employed artificial intelligence (AI) analysis to quantify the mean size of intratumoral CD8+ T cells in each sample. Patients were then divided into "Large" and "Small" CD8+ T cell groups according to the median T-cell size. Similarly, we classified cases into "High" and "Low" groups based on CD8 + T-cell numbers. We found that patients in the Large CD8+ T cell group had significantly better overall survival than those in the Small CD8+ T cell group by a univariate analysis (p = 0.039), but the difference did not reach statistical significance in a multivariate analysis (p = 0.054). Patients in the High CD8 + T cell group had better outcomes than those in the Low CD8+ T cell group. There was no significant correlation between CD8+ T cell size and count, and their combination (Large/High) identified a subgroup of patients with the most favorable prognosis. Our findings suggest that CD8+ T cell size could serve as an independent prognostic marker in ESCC.

    DOI: 10.1038/s41598-025-10885-3

    PubMed

    researchmap

  • Dual onsets of small cell lung cancer with contrasting neuroendocrine features and immune microenvironments: A case report. 国際誌

    Toshiyuki Sumi, Taiki Ishigooka, Keigo Matsuura, Takumi Ikeda, Yuichi Yamada, Naoki Shijubou, Terufumi Kubo, Hirofumi Chiba

    Lung cancer (Amsterdam, Netherlands)   201   108420 - 108420   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Small cell lung cancer (SCLC) is an aggressive malignancy with a poor prognosis and limited therapeutic options. Immune checkpoint inhibitors (ICIs) offer modest survival benefits; however, their efficacy is inconsistent, and only a few reliable biomarkers are available for guiding treatment. The molecular subtypes of SCLC, defined by transcription factor expression (SCLC-A, SCLC-N, SCLC-P, and SCLC-Y), exhibit distinct therapeutic vulnerabilities. Among these, the SCLC-I subtype, characterized by low neuroendocrine differentiation and high immune activity, is associated with an improved response to ICIs. However, the implications of the subtype transitions during disease progression remain unclear. Here, we describe the case of a patient in their 60 s who developed SCLC twice, presenting with distinct neuroendocrine features and immune profiles. The initial tumor, classified as SCLC-I, exhibited significant CD8 + T-cell infiltration and negative ASCL1/NEUROD1 expression, which correlated with a prolonged atezolizumab response. Three years later, a newly developed tumor in the contralateral lung displayed SCLC-A features, with ASCL1/NEUROD1 positivity and an absence of CD8 + infiltration, resulting in limited durvalumab efficacy. This report highlights the dynamic nature of SCLC and the importance of histopathological evaluation for guiding treatment. Larger studies are needed to validate the generalizability of these findings and explore biomarkers for diagnostic strategies.

    DOI: 10.1016/j.lungcan.2025.108420

    PubMed

    researchmap

  • MHC class I trafficking signal improves induction of cytotoxic T lymphocyte using artificial antigen presenting cells. 国際誌

    Kenta Sasaki, Kenji Murata, Tomoyuki Minowa, Naoki Shijubou, Hiroki Kobayashi, Munehide Nakatsugawa, Aiko Murai, Yuka Mizue, Terufumi Kubo, Takayuki Kanaseki, Tomohide Tsukahara, Hisashi Uhara, Akemi Ishida-Yamamoto, Yoshihiko Hirohashi, Toshihiko Torigoe

    Biochemistry and biophysics reports   41   101946 - 101946   2025年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Inducing antigen peptide-specific cytotoxic T cells is challenging, partly due to the difficulty of maintaining the quality of antigen-presenting cells, such as dendritic cells. Consequently, artificial antigen-presenting cells (aAPCs) derived from the erythroleukemia cell line K562 have been employed for T cell stimulation. K562-based aAPCs can be utilized for both non-specific and antigen-specific T cell stimulation. Antigen peptide-pulsed aAPCs are commonly used to stimulate T cells with known specific antigenic peptides, which require identifying antigenic peptides from cognate antigen proteins. Therefore, antigen gene-overexpressing aAPCs might be useful for detecting unknown antigenic peptides. In this study, we evaluated the efficacy of cytotoxic T lymphocyte (CTL) induction using antigen gene-overexpressing aAPCs. To enhance antigen presentation efficiency, we assessed the signal peptide (SP) fused with MHC class I trafficking signal (MITD) sequences (SP-MITD). SP-MITD, fused with epitopes from the neoantigen AKF9 and the viral antigen CMVpp65, was transduced into aAPCs. We compared the CTL induction ability of peptide-pulsed aAPCs, only mini-gene-overexpressing aAPCs [SP-MITD (-)], and mini-gene fused with SP-MITD overexpressing aAPCs [SP-MITD (+)]. The SP-MITD (+) gene-overexpressing aAPCs exhibited the highest CTL induction efficiency compared to both peptide-pulsed and SP-MITD (-) gene-overexpressing aAPCs. These findings suggest that antigen gene-fused with SP-MITD transduced aAPCs are highly effective for inducing CTLs specific to both known and unknown antigenic peptides.

    DOI: 10.1016/j.bbrep.2025.101946

    PubMed

    researchmap

  • Establishment of potent TCR-T cells specific for cisplatin-resistance related tumor-associated antigen, CLSPN using codon-optimization. 国際誌

    Kanta Hori, Shuhei Yamada, Kenji Murata, Haruka Miyata, Yuka Mizue, Aiko Murai, Tomoyuki Minowa, Kenta Sasaki, Naoki Shijubou, Terufumi Kubo, Rena Morita, Serina Tokita, Takayuki Kanaseki, Tomohide Tsukahara, Takashige Abe, Nobuo Shinohara, Yoshihiko Hirohashi, Toshihiko Torigoe

    Human vaccines & immunotherapeutics   20 ( 1 )   2414542 - 2414542   2024年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Adoptive T cell therapy, using T cell receptor-engineered T (TCR-T) cells and chimeric antigen receptor T (CAR-T) cells, is a potent immunotherapy option. Bladder cancer is a prevalent urological malignancy, particularly in cases of muscle invasion and metastasis, for which systemic therapy is crucial. Immunotherapy utilizing immune checkpoint blockade has been approved for bladder cancer treatment. The antitumor effect of an immune checkpoint blockade based on cytotoxic T cells (CTLs) and the patient's immune status is essential. The chemotherapeutic drug cisplatin (CDDP) is a key drug in bladder cancer treatment. However, it has been shown to suppress T cells, making combination therapy with CDDP and immunotherapy difficult. To address this, we developed TCR-T cells specific for bladder cancer cells. In previous studies, we found that the tumor-associated antigen CLSPN is overexpressed in CDDP-resistant bladder cancer cells and that the antigenic peptide HLA-A*02:01/CLSPN1254-1262, encoded by CLSPN, could be targeted by a CTL clone. The TCR was cloned from the HLA-A*02:01/CLSPN1254-1262 specific CTL clone yc3. We also designed a codon-optimized TCR sequence using GeneArt® GeneOptimizer® (Opt TCR) and compared the TCR-T cells using the original TCR sequence (Ori TCR-T cells) and the codon-optimized TCR sequence (Opt TCR-T cells). Opt TCR-T cells exhibited higher TCR transduction efficiency, higher TCR expression levels, higher avidity, and greater cytotoxicity than did Ori TCR-T cells. These results suggest that HLA-A*02:01/CLSPN1254-1262 specific Opt TCR-T cells are promising candidates for CDDP combination therapy.

    DOI: 10.1080/21645515.2024.2414542

    PubMed

    researchmap

  • Risk factors for severe immune-related pneumonitis after nivolumab plus ipilimumab therapy for non-small cell lung cancer. 国際誌

    Toshiyuki Sumi, Motoki Sekikawa, Yuta Koshino, Daiki Nagayama, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Keito Suzuki, Takumi Ikeda, Haruhiko Michimata, Hiroki Watanabe, Yuichi Yamada, Koichi Osuda, Yusuke Tanaka, Hirofumi Chiba

    Thoracic cancer   15 ( 20 )   1572 - 1581   2024年7月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: The efficacy of anti-CTLA-4 antibody (ipilimumab) plus anti-programmed cell death 1 antibody (nivolumab) in treating advanced non-small cell lung cancer (NSCLC) is impeded by an elevated risk of severe immune-related adverse events. However, our understanding of associations among pre-existing fibrosis, emphysematous changes, and objective indicators as predictive factors is limited for severe pneumonitis in NSCLC patients receiving this combination therapy. Thus, we retrospectively investigated these associations, including overall tumor burden, before treatment initiation in the Japanese population. METHODS: We focused on patients (n = 76) with pre-existing interstitial lung disease (ILD) to identify predictors of severe pneumonitis. Variables included age, sex, smoking status, programmed cell death ligand 1 expression, overall tumor burden, chest computed tomography-confirmed fibrosis, serum markers, and respiratory function test results. RESULTS: Severe pneumonitis was more frequent in patients with squamous cell carcinoma, fibrosis, low diffusing capacity for carbon monoxide (%DLCO), and high surfactant protein D (SP-D) level. Notably, squamous cell carcinoma, baseline %DLCO, and SP-D level were significant risk factors. Our findings revealed the nonsignificance of tumor burden (≥85 mm) in predicting severe pneumonitis, emphasizing the importance of pre-existing ILD. Conversely, in cases without pre-existing fibrosis, severe pneumonitis was not associated with %DLCO or SP-D level (93.2% vs. 91.9%, and 63.3 vs. 40.9 ng/mL, respectively) and was more common in patients with a large overall tumor burden (97.5 vs. 70.0 mm). CONCLUSION: Vigilant monitoring and early intervention are crucial for patients with squamous cell carcinoma, high SP-D level, or low %DLCO undergoing ipilimumab plus nivolumab therapy.

    DOI: 10.1111/1759-7714.15385

    PubMed

    researchmap

  • Prognostic significance of immunohistochemical classification utilizing biopsy specimens in patients with extensive-disease small-cell lung cancer treated with first-line chemotherapy and immune checkpoint inhibitors. 国際誌

    Naoki Shijubou, Toshiyuki Sumi, Terufumi Kubo, Kenta Sasaki, Tomohide Tsukahara, Takayuki Kanaseki, Kenji Murata, Yoshiko Keira, Kotomi Terai, Tatsuru Ikeda, Yuichi Yamada, Hirofumi Chiba, Yoshihiko Hirohashi, Toshihiko Torigoe

    Journal of cancer research and clinical oncology   150 ( 3 )   125 - 125   2024年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Although immune checkpoint inhibitors (ICIs), together with cytotoxic chemotherapy (chemoimmunotherapy), have been adapted for the initial treatment of extensive-disease small-cell lung cancer (ED-SCLC), they have achieved limited success. In ED-SCLC, a subtype of SCLC, the expression of immune-related molecules and clinical data are not well understood in relation to ICI treatment efficiency. METHODS: We examined lung biopsy specimens from patients diagnosed with ED-SCLC treated with chemoimmunotherapy or chemotherapy. SCLC subtype, expression of HLA class I, and infiltration of CD8-positive cells were examined using immunohistochemistry (IHC). Subsequently, the association between clinical factors, IHC results, and progression-free survival or overall survival was assessed. RESULTS: Most of the cases showed the achaete-scute homolog 1 (ASCL1) subtype. Among the 75 SCLC cases, 29 expressed high levels of HLA class I, while 46 showed low levels or a negative result; 33 patients were characterized as CD8-high, whereas 42 were CD8-low. In the chemoimmunotherapy cohort, multivariate analysis revealed a correlation between CD8-high and improved survival. Specifically, patients in the CD8-high group of the chemoimmunotherapy cohort experienced enhanced survival compared to those in the chemotherapy cohort, which was attributed to ICI addition. IHC subtype analysis demonstrated a survival advantage in the SCLC-I and SCLC-A groups when ICI was combined with chemotherapy compared to chemotherapy alone. CONCLUSION: Our study highlights the predictive value of IHC-classified subtypes and CD8-positive cell infiltration in estimating outcomes for patients with ED-SCLC treated with chemoimmunotherapy as a first-line therapy. These findings have practical implications for daily clinical assessments and treatment decisions.

    DOI: 10.1007/s00432-024-05652-2

    PubMed

    researchmap

  • Anti-CTLA-4 Antibody Might Be Effective Against Non-small Cell Lung Cancer With Large Size Tumor. 国際誌

    Hiroshi Saijo, Yoshihiko Hirohashi, Osamu Honjo, Toyohiro Saikai, Naoki Shijubo, Hirotsugu Takabatake, Akihisa Fujita, Yasuhito Honda, Hiroyuki Koba, Hirofumi Chiba, Toshihiko Torigoe

    Anticancer research   43 ( 9 )   4155 - 4160   2023年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND/AIM: Immunotherapy using immune checkpoint inhibitors (ICIs) has revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). Although several ICI options are available, the treatment regimen for NSCLC with large size tumors (large NSCLC) is controversial and the efficacy of anti-CTLA-4 antibody is unclear. This study thus investigated potential biomarkers for CTLA-4 blockade. PATIENTS AND METHODS: The correlation between tumor diameter and treatment duration was examined in patients with advanced NSCLC treated with anti-PD-1 antibody monotherapy in our institution. In addition, the ratio of tumor-infiltrating CD8+ T cells and regulatory T (Treg) cells in small and large size NSCLC was also evaluated using immunohistochemical staining. Finally, the efficacy of treatment with anti-CTLA-4 antibody against large NSCLC was investigated. RESULTS: A negative correlation was found between tumor diameter and treatment duration in patients treated with anti-PD-1 antibody monotherapy. Immuno-histochemical staining revealed that Treg cell infiltration was significantly higher in large NSCLC tumors than in small tumors. Among the patients with large NSCLC, the ICI regimen including anti-CTLA-4 antibody showed significant efficacies. CONCLUSION: Anti-PD-1 antibody monotherapy might be less effective against large NSCLC due to the infiltration of Treg cells. Therefore, it might be appropriate for large NSCLC to select a treatment including an anti-CTLA-4 antibody, which can target Treg cells.

    DOI: 10.21873/anticanres.16606

    PubMed

    researchmap

  • CD8陽性細胞の浸潤の有無は,化学療法と免疫チェックポイント阻害薬を施行した進展型小細胞肺癌の予後を規定する(Infiltration of CD8 positive cells into ED-SCLC determines the prognosis of patients received chemo-immunotherapy)

    四十坊 直貴, 久保 輝文, 佐々木 健太, 角 俊行, 廣橋 良彦, 鳥越 俊彦

    日本癌学会総会記事   82回   1398 - 1398   2023年9月

     詳細を見る

    記述言語:英語   出版者・発行元:(一社)日本癌学会  

    医中誌

    researchmap

  • Metastatic pulmonary pleomorphic carcinoma replaced by a granulomatous lesion after spontaneous regression and PD-1 blockade-induced regression: can epithelioid granuloma be a histological hallmark of cancer immunity? 国際誌

    Naoki Shijubou, Yuichiro Asai, Michiko Hosaka, Keiko Segawa, Terufumi Kubo, Masahiro Miyajima, Tomohide Tsukahara, Yoshihiko Hirohashi, Takayuki Kanaseki, Kenji Murata, Atsushi Watanabe, Tadashi Hasegawa, Hirofumi Chiba, Toshihiko Torigoe

    Immunological medicine   46 ( 2 )   93 - 96   2023年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Immune checkpoint inhibitors (ICIs) for various types of malignancy, including non-small-cell lung cancer, have improved prognosis in some cases. Granuloma formation after ICI administration suggests a tumor antigen-specific cytotoxic T cell response with abundant interferon-gamma production, which can be used to estimate the curative effect of ICIs. In this report, we present a case with a resected lung lesion, clinically suspected to be lung cancer, that consisted of a granulomatous lesion. A tumor was also found in the duodenum that was presumed to be derived from the pulmonary pleomorphic carcinoma. Duodenal tumor cells highly expressed PD-L1, suggesting PD-1/PD-L1 axis-mediated immune escape. As expected, pembrolizumab induced a complete response for the duodenal lesion. Interestingly, in histopathological analysis, the duodenal lesion was also replaced by an epithelial granuloma and multinucleated giant cells. We conclude that autoimmunity regressed the untreated primary lung lesion spontaneously, while the metastatic duodenal lesion responded to PD-1 blockade. Tumor-associated epithelioid granulomas, even before ICI administration, may be an important pathological finding indicating an immune response with interferon-gamma production by cytotoxic T cells to the tumor.

    DOI: 10.1080/25785826.2023.2193283

    PubMed

    researchmap

  • Autoimmune Pulmonary Alveolar Proteinosis during the Treatment of Idiopathic Inflammatory Myopathy.

    Naoki Shijubou, Takeyuki Sawai, Taku Hatakeyama, Satoru Munakata, Masami Yamazoe, Hirofumi Chiba

    Internal medicine (Tokyo, Japan)   62 ( 3 )   445 - 448   2023年2月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Approximately 50% of idiopathic inflammatory myopathies (IIMs) are associated with interstitial lung disease (ILD). Typically, IIM-ILD manifests as nonspecific interstitial pneumonia. We herein report a rare case of a 78-year-old man with autoimmune pulmonary alveolar proteinosis (PAP) that developed during IIM treatment. The diagnosis of autoimmune PAP was based on detecting anti-granulocyte-macrophage colony-stimulating factor antibodies. We postulated that PAP may have been induced by IIM treatment with prednisolone. Our case suggests that the possibility of autoimmune PAP should be considered in patients with lung lesions during the clinical course of IIM.

    DOI: 10.2169/internalmedicine.9558-22

    PubMed

    researchmap

  • Relation of overall tumor burden with severe immune-related adverse events in nivolumab plus ipilimumab treatment for lung cancer. 国際誌

    Toshiyuki Sumi, Motoki Sekikawa, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Hiroki Watanabe, Yuichi Yamada, Yusuke Tanaka, Hirofumi Chiba

    Investigational new drugs   40 ( 6 )   1315 - 1321   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Compared to chemotherapy alone, monoclonal antibodies like ipilimumab and nivolumab, with or without chemotherapy, improve the prognosis of patients with non-small cell lung cancer (NSCLC), albeit with a higher incidence of immune-related adverse events (irAEs) than those with immune checkpoint inhibitor (ICI) monotherapy. Therefore, we aimed to investigate if baseline overall tumor burden was associated with the development of Grade ≥ 3 irAEs (severe irAEs) when treated with first-line ipilimumab plus nivolumab with or without chemotherapy.We retrospectively examined consecutive patients with advanced NSCLC who received nivolumab plus ipilimumab with or without chemotherapy at Hakodate Goryoukaku Hospital between December 2020 and December 2021. Baseline overall tumor burden was measured as the sum of unidimensional diameters of up to five target lesions according to the Response Evaluation Criteria in Solid Tumors, version 1.1. We defined irAEs as ICI therapy-related toxicities according to the Common Terminology Criteria for Adverse Events, version 5.0.A significant difference in tumor burden was observed between patients with and without severe irAEs (100 mm vs. 67.5 mm, p = 0.001). We evaluated various clinical parameters, including baseline overall tumor burden, before treatment initiation. Of the various parameters, only high tumor burden correlated with severe irAEs, independent of complementary chemotherapy. The multivariate odds ratio of severe irAEs and high tumor burden was 6.62.Conclusively, baseline overall tumor burden may be a risk factor for severe irAEs in patients treated with first-line combination ICI therapy. Therefore, patients with large tumor burden should be carefully monitored to prevent irAEs.

    DOI: 10.1007/s10637-022-01305-8

    PubMed

    researchmap

  • Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer. 国際誌

    Toshiyuki Sumi, Yuta Koshshino, Motoki Sekikawa, Yuta Nagahisa, Keigo Matsuura, Naoki Shijubou, Koki Kamada, Hiroki Watanabe, Haruhiko Michimata, Daiki Nagayama, Yusuke Tanaka, Yuichi Yamada, Hirofumi Chiba

    Investigational new drugs   40 ( 6 )   1298 - 1305   2022年12月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pembrolizumab treatment is associated with a favorable prognosis in patients with non-small-cell lung cancer (NSCLC). Here, we investigated the associations among pre-treatment clinical factors, baseline overall tumor burden, and development of severe immune-related adverse events (irAEs; grade ≥ 3) after pembrolizumab treatment with or without chemotherapy. We retrospectively examined consecutive patients with advanced NSCLC who received pembrolizumab with or without chemotherapy at Hakodate Goryoukaku Hospital from March 2017 to February 2021. The baseline overall tumor burden was measured as the sum of the unidimensional diameters of up to five target lesions. We defined irAEs as toxicities related to immune checkpoint inhibitors based on the Common Terminology Criteria for Adverse Events, version 5.0. Tumor burden differed significantly between patients with and without severe irAEs (85 vs. 65 mm, p = 0.0367). The cutoff value for overall tumor burden was set to 80 mm. Good performance status (PS = 0) and PD-L1 expression > 80%, but not overall tumor burden, were correlated with severe irAEs, regardless of complementary chemotherapy. The multivariate odds ratios of good PS and high PD-L1 expression for severe irAEs were 3.27 (95% confidence interval [CI]: 1.22-8.77, p = 0.019) and 4.44 (95% CI: 1.59-12.42, p = 0.0044), respectively. Baseline overall tumor burden, good PS, and high PD-L1 expression were associated with severe irAEs in patients with NSCLC treated with first-line pembrolizumab with or without chemotherapy. Patients with these factors should be carefully monitored to prevent irAEs.

    DOI: 10.1007/s10637-022-01310-x

    PubMed

    researchmap

  • Immunological and nutritional predictive factors in patients receiving pembrolizumab for the first-line treatment of non-small cell lung cancer. 国際誌

    Naoki Shijubou, Toshiyuki Sumi, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba

    Journal of cancer research and clinical oncology   148 ( 8 )   1893 - 1901   2022年8月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    PURPOSE: Immune checkpoint inhibitors (ICIs) have prolonged the survival of patients with various carcinomas, including non-small cell lung cancer (NSCLC), and have caused a paradigm shift in cancer treatment. Although programmed death-ligand 1 (PD-L1) expression in tumor cells is a predictive marker of therapeutic efficacy, additional predictive markers are required. This study aimed to explore the role of immunological and nutritional parameters in the prediction of treatment response. METHODS: Patients diagnosed with NSCLC and treated with pembrolizumab were examined retrospectively. Body weight was measured 4-6 weeks before the start of the first treatment, immediately before treatment, and 4-6 weeks after the start of the first treatment. Progression-free survival (PFS) was defined as the time from the start of pembrolizumab treatment to the last follow-up date or until disease progression. Statistical analyses were performed to confirm the association between various factors and association between these factors and PFS. RESULTS: Thirty-eight patients with advanced NSCLC were included. We observed a significant association of weight loss and PD-L1 expression with PFS in the multivariate analysis. A significant correlation was found between the advanced lung cancer inflammation index and neutrophil-to-lymphocyte ratio. A weight loss of > 5% after the start of treatment was significantly associated with worse PFS. CONCLUSIONS: Weight loss is an important negative prognostic factor in patients with NSCLC receiving immunotherapy. Weight maintenance may be important for good ICI treatment efficacy, and future interventions in cancer cachexia are expected to further enhance the treatment efficacy of ICIs.

    DOI: 10.1007/s00432-022-03941-2

    PubMed

    researchmap

  • Alveolar Hemorrhage Caused by the Combination of Immune Checkpoint Inhibitors (ICIs) and Angiogenesis Inhibitors: The Underlying Long-Term Vascular Endothelial Growth Factor (VEGF) Inhibition. 国際誌

    Naoki Shijubou, Takeyuki Sawai, Taku Hatakeyama, Satoru Munakata, Masami Yamazoe

    Cureus   14 ( 3 )   e23272   2022年3月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    The combination of immune checkpoint inhibitors (ICIs) and other anticancer agents is the standard of care for various cancers. Bevacizumab, an anti-angiogenesis inhibitor, causes serious adverse events such as pulmonary hemorrhage (PH). Here, we present a case of drug-induced diffuse alveolar hemorrhage (DAH), an adverse event, in a patient with hepatocellular carcinoma who was treated with a combination of ICIs and anti-angiogenesis inhibitors after long-term use of lenvatinib, which inhibits vascular endothelial growth factor (VEGF). An 85-year-old man with hepatocellular carcinoma initially received lenvatinib, a multi-kinase inhibitor, but the drug was later switched to bevacizumab-atezolizumab combination therapy owing to disease progression. After five cycles, he developed dyspnea and diffuse ground-glass opacities, which improved with discontinuation of the combination therapy and initiation of steroid pulse therapy. Our case findings indicate that both ICIs and anti-angiogenesis inhibitors cause drug-induced DAH, and their combination may increase the severity of DAH. Moreover, long-term VEGF inhibition may induce the development of DAH. Clinicians need to be aware that long-term VEGF inhibition may be associated with DAH and should consider the risk management of such adverse events while using this combination therapy.

    DOI: 10.7759/cureus.23272

    PubMed

    researchmap

  • Transbronchial needle aspiration with endobronchial ultrasonography and ultrathin bronchoscopy for peripheral pulmonary lesions. 国際誌

    Toshiyuki Sumi, Naoki Shijubou, Takeyuki Sawai, Koki Kamada, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba

    Respiratory investigation   59 ( 6 )   766 - 771   2021年11月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Although the efficacy of lung cancer treatment has improved, it is dependent on a reliable diagnosis via bronchoscopy. Transbronchial biopsy using ultrathin bronchoscopy can help detect small peripheral pulmonary lesions (PPLs), with a high diagnostic yield. However, the diagnosis rate using forceps biopsy when the radial endobronchial ultrasonography (rEBUS) probe is adjacent to a lesion tends to be low. Transbronchial needle aspiration (TBNA) may improve the diagnostic yield from adjacent lesions. Recently, PeriView FLEX, a new TBNA needle that can be inserted into ultrathin bronchoscopes, has become available. We examined whether TBNA with PeriView FLEX and forceps biopsy improved adjacent lesion diagnosis when using ultrathin bronchoscopes. METHODS: We retrospectively examined 51 consecutive patients who underwent TBNA and forceps biopsy using ultrathin bronchoscopes under rEBUS for small PPLs at the Hakodate Goryoukaku Hospital between November 2019 and August 2020. The histological diagnosis rate using TBNA and forceps biopsy, TBNA alone, or forceps biopsy alone was compared between cases where the rEBUS probe was "Within" and "Adjacent To" the lesions. RESULTS: The diagnosis rate using TBNA and forceps biopsy was 86.3% (95.7% vs. 78.6%; p = 0.08) for all lesions (Within cases vs. Adjacent To cases). The corresponding rate using TBNA alone was 68.6% (69.6% vs. 67.9%; p = 0.57), and that using forceps biopsy alone was 72.5% (91.3% vs. 57.1%; p = 0.0067). CONCLUSIONS: Forceps biopsy with TBNA during ultrathin bronchoscopy for small PPLs improved the diagnostic yield when lesions were adjacent to the rEBUS probe.

    DOI: 10.1016/j.resinv.2021.04.004

    PubMed

    researchmap

  • Pseudocirrhosis due to liver metastasis from lung adenocarcinoma. 国際誌

    Naoki Shijubou, Toshiyuki Sumi, Yoshiko Keira, Hideaki Shiraishi, Yuta Nagahisa, Keigo Matsuura, Motoki Sekikawa, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba

    Thoracic cancer   12 ( 17 )   2407 - 2410   2021年9月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Pseudocirrhosis is a radiological diagnosis of cirrhosis without histological evidence and occurs as a complication of liver metastases from solid tumors. A 50-year-old man without any previous history of liver disease was diagnosed with adenocarcinoma of the left upper lung lobe and liver metastasis. After chemotherapy, the liver metastases shrank; however, over time, the liver shrank and showed cirrhosis-like morphological changes. His performance status deteriorated due to ascites and leg edema, and chemotherapy was terminated. Physicians treating lung adenocarcinoma with liver metastases should be aware that pseudocirrhosis is a rare but important complication that can worsen performance status (PS) and hinder treatment continuation.

    DOI: 10.1111/1759-7714.14084

    PubMed

    researchmap

  • Long-term response to osimertinib in elderly patients with lung adenocarcinoma harbouring de novo EGFR T790M: a case report and literature review. 国際誌

    Toshiyuki Sumi, Koki Kamada, Naoki Shijubou, Yuichi Yamada, Hisashi Nakata, Yuji Mori, Hirofumi Chiba

    Respirology case reports   9 ( 6 )   e00759   2021年6月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Osimertinib is a potent and irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) that selectively acts on both EGFR-sensitive and EGFR T790M-resistant mutations. Patients with pre-treatment EGFR T790M mutations (de novo EGFR T790M) respond poorly to existing EGFR-TKIs, whereas osimertinib has positive effects. However, the safety data for first-line osimertinib treatment in patients aged >75 years are insufficient. We treated two elderly patients with de novo EGFR T790M mutations with osimertinib as the first-line therapy. We found that the first-line treatment with osimertinib was safe and resulted in a long-term response in elderly patients with de novo EGFR T790M-mutated lung adenocarcinoma.

    DOI: 10.1002/rcr2.759

    PubMed

    researchmap

  • Fulminant amebic colitis in a patient with concomitant cytomegalovirus infection after systemic steroid therapy: A case report. 国際誌

    Naoki Shijubou, Toshiyuki Sumi, Koki Kamada, Takeyuki Sawai, Yuichi Yamada, Tatsuru Ikeda, Hisashi Nakata, Yuji Mori, Hirofumi Chiba

    World journal of clinical cases   9 ( 15 )   3726 - 3732   2021年5月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    BACKGROUND: Amebic colitis is an infection caused by Entamoeba histolytica and most commonly observed in regions with poor sanitation. It is also seen as a sexually transmitted disease in developed countries. While amebic colitis usually has a chronic course with repeated exacerbations and remissions, it may also manifest as a fulminant form that rapidly progresses and leads to severe, life-threatening complications, such as intestinal perforation, peritonitis, and sepsis, that have a high mortality rate. CASE SUMMARY: A 68-year-old man was admitted to our hospital with chest pain and acute dyspnea. He was diagnosed with acute coronary syndrome, acute heart failure, and bacterial pneumonia. His respiratory condition worsened despite receiving intensive care and intravenous antibiotics. On the fifth day of hospitalization, he was diagnosed with acute respiratory distress syndrome and was started on steroid therapy. He subsequently developed bloody stools and was diagnosed with cytomegalovirus (CMV) enterocolitis based on biopsy results and a peripheral blood CMV pp65 antigenemia test result. Although we started antiviral therapy with ganciclovir, which was successful in reducing his antigen titers, he continued to have bloody diarrhea. Three weeks after initiation of ganciclovir therapy and six weeks after his admission, the patient died from intestinal perforation. We only posthumously diagnosed him with amebic colitis and CMV enterocolitis based on autopsy findings of transmural necrosis of the entire colon with massive ameba infiltration. CONCLUSION: We urge clinicians to consider Entamoeba histolytica infection if severe colitis progresses after steroid therapy. Preemptive treatment is recommended then.

    DOI: 10.12998/wjcc.v9.i15.3726

    PubMed

    researchmap

  • Diffuse alveolar haemorrhage due to pheochromocytoma crisis. 国際誌

    Naoki Shijubou, Toshiyuki Sumi, Koki Kamada, Yuichi Yamada, Hisashi Nakata, Hirofumi Chiba

    Respirology case reports   9 ( 4 )   e00722   2021年4月

     詳細を見る

    記述言語:英語   掲載種別:研究論文(学術雑誌)  

    Clinicians should be aware that interstitial shadows with extreme hypertension should be considered as indicators for diffuse alveolar haemorrhage due to pheochromocytoma crisis.

    DOI: 10.1002/rcr2.722

    PubMed

    researchmap

  • 末梢肺病変に対する極細径気管支鏡を用いたEBUS併用経気管支針生検(EBUS-UTTBNA)の検討

    澤井 健之, 角 俊行, 四十坊 直貴, 山田 裕一, 中田 尚志, 森 裕二, 高橋 弘毅

    気管支学   42 ( Suppl. )   S236 - S236   2020年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器内視鏡学会  

    医中誌

    researchmap

  • 仮想気管支鏡を用いない場合の末梢肺病変に対する極細径気管支鏡と通常気管支鏡の診断率の比較

    角 俊行, 池田 拓海, 澤井 健之, 四十坊 直貴, 呉 賢一, 山田 裕一, 中田 尚志, 森 裕二, 高橋 弘毅

    気管支学   42 ( Suppl. )   S239 - S239   2020年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器内視鏡学会  

    医中誌

    researchmap

  • 進行期肺癌に合併した有瘻性膿胸に対して胸腔鏡および気管支鏡を併用しEWS牽引固定術を施行した1例

    佐藤 太軌, 角 俊行, 澤井 健之, 四十坊 直貴, 山田 裕一, 上原 浩文, 正岡 俊明

    気管支学   42 ( Suppl. )   S231 - S231   2020年6月

     詳細を見る

    記述言語:日本語   出版者・発行元:(一社)日本呼吸器内視鏡学会  

    医中誌

    researchmap

▼全件表示

MISC

▼全件表示

共同研究・競争的資金等の研究課題

  • がん幹細胞抗原DNAJB8標的免疫療法のSCLCへの有効性検証と診断基盤の確立

    研究課題/領域番号:26K18592  2026年4月 - 2029年3月

    日本学術振興会  科学研究費助成事業  若手研究

    四十坊 直貴

      詳細を見る

    配分額:4550000円 ( 直接経費:3500000円 、 間接経費:1050000円 )

    researchmap